1
|
Kuijper SC, Pape M, Haj Mohammad N, Van Voorthuizen T, Zwinderman AH, Verhoeven R, Van Laarhoven HW. SOURCE beyond first-line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first-line palliative systemic therapy. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.4037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4037 Background: Prediction models for survival may aid shared decision making between physicians and patients. Prior models have been developed that predict survival for patients with potentially curable esophagogastric cancer and patients with metastatic esophageal cancer who start first-line therapy (the SOURCE models). The aim of this study was to develop and internally validate a registry-based clinical prediction model, called SOURCE beyond first-line, for survival of patients with metastatic esophagogastric cancer after failure of first-line palliative systemic therapy. Methods: Patients with unresectable or metastatic (synchronous or metachronous) esophageal or gastric cancer who received first-line systemic therapy (N = 1067) between 2015-2017 were selected from the Netherlands Cancer Registry. Follow-up data were retrieved in 2019. Patient, tumor and treatment characteristics at primary diagnosis and at progression of disease, were used to develop the prediction model. A Cox proportional hazards regression prediction model was developed through forward and backward selection using Akaike’s Information Criterion. The model was internally validated through 10-fold cross-validations to assess performance on unseen data. Model discrimination (C-index) and calibration (slope and intercept) were used to evaluate performance of the complete and cross-validated models. Results: The final model consisted of 10 patient, tumor and treatment characteristics. The C-index was 0.75 (0.74-0.77), the calibration slope 0.99 (0.98-0.99) and the calibration intercept 0.02 (0.01-0.02). Internal cross-validation of the model showed that the model performed adequately on unseen data: C-index 0.79 (0.76-0.80), calibration slope 1.02 (1.00-1.04) and calibration intercept -0.01 (-0.01-0.02). Conclusions: The SOURCE beyond first-line model predicted survival with fair discriminatory ability and good calibration, and is a valuable addition to the existing SOURCE prediction models. In the future this model will be integrated in an online decision support tool that can be used in clinical practice to aid personalized treatment.
Collapse
Affiliation(s)
| | - Marieke Pape
- Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands
| | - Nadia Haj Mohammad
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht, Netherlands
| | | | - Aeilko H. Zwinderman
- Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, Amsterdam, Netherlands
| | - Rob Verhoeven
- Netherlands Comprehensive Cancer Organisation, Eindhoven, Netherlands
| | - Hanneke W.M. Van Laarhoven
- Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands
| |
Collapse
|
2
|
Punt CJA, Simkens LH, Van Rooijen J, Van de Wouw AW, Loosveld O, Creemers GJ, Hendriks MP, Los M, Van Alphen RJ, Polee M, Muller EW, Van Der Velden A, Van Voorthuizen T, Koopman M, Mol L, Kwakman JJ, van Werkhoven ED. Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.3640] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Cornelis J. A. Punt
- Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | | | | | | | | | - Geert-Jan Creemers
- Department of Medical Oncology, Catharina Hospital, Eindhoven, Netherlands
| | | | - Maartje Los
- St. Antonius Hospital, Nieuwegein, Netherlands
| | | | - Marco Polee
- Medical Center Leeuwarden, Leeuwarden, Netherlands
| | | | | | | | - Miriam Koopman
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Linda Mol
- Netherlands Comprehensive Cancer Organization, Nijmegen, Netherlands
| | | | | |
Collapse
|
3
|
Dierks J, Coelen RJ, De Groot JW, Ten Tije AJ, Meijer W, Pruijt H, Van Voorthuizen T, van Spronsen DJ, ten Oever D, Smit JM, Otten HM, van Gulik TM, Wilmink J, Klümpen HJ. Translating a clinical trial to daily practice: Outcome of palliative treatment in patients with advanced cholangiocarcinoma and gallbladder cancer in the Netherlands. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e15596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | - Hans Pruijt
- Jeroen Bosch Hospital, Hertogenbosch, Netherlands
| | | | | | | | - J. M. Smit
- Gelre Hospital Apeldoorn, Apeldoorn, Netherlands
| | | | | | | | | |
Collapse
|